DexCom receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
DexCom Inc (DXCM)
DexCom Inc stock price live, this page displays NASDAQ DXCM stock exchange data. View the DXCM premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the DexCom Inc real time stock price chart below.
What Is the DexCom Inc Stock Price Today?
The DexCom Inc stock price today is 79.68.
What Is the Stock Symbol for DexCom Inc?
The stock symbol for DexCom Inc is "DXCM."
What Stock Exchange Does DexCom Inc Trade On?
DexCom Inc is listed and trades on the NASDAQ stock exchange.
Is DexCom Inc a Good Stock to Buy?
Determining whether DexCom Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DXCM quote. (ISIN: US2521311074)
What Is the DexCom Inc Stock Price Today?
The DexCom Inc stock price today is 79.68.
What Is the Stock Symbol for DexCom Inc?
The stock symbol for DexCom Inc is "DXCM."
What Stock Exchange Does DexCom Inc Trade On?
DexCom Inc is listed and trades on the NASDAQ stock exchange.
Is DexCom Inc a Good Stock to Buy?
Determining whether DexCom Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DXCM quote. (ISIN: US2521311074)
79.68
-4.78(-5.66%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
79.28
82.85
52 wk Range
54.11
92.59
DXCM is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
79.2882.85
52 wk Range
54.1192.59
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DXCM Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
98.15
Upside
+23.19%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Management has been aggressively buying back shares
DexCom receives Investment Bank Analyst Rating Update- Investing.com
Pro
DexCom receives Investment Bank Analyst Rating Update- Investing.com
Pro
- DexCom receives Investment Bank Analyst Rating Update
- Investing.com
Pro - DexCom receives Investment Bank Analyst Rating Update
- Investing.com
Pro - DexCom receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
DexCom receives Investment Bank Analyst Rating Update- Investing.com
Pro- DexCom receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
26 Buy
3 Hold
0 Sell
Ratings:
29 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 98.15
(+23.19% Upside)
DexCom Inc SWOT Analysis
Diabetes Tech Leade | DexCom dominates the continuous glucose monitoring market with strong sales growth and record new patient starts, despite facing recent margin pressures from supply chain challenges. |
Growth Catalysts | Expansion into the Type 2 diabetes market and the upcoming G7 15-day sensor launch present significant opportunities, with 6 million new covered lives expected by year-end 2025. |
Financial Headwinds | Despite robust sales of $1.04 billion in Q1 2025, DexCom faces margin challenges from quality initiatives and supply issues, prompting revised forecasts for 2026. |
Analyst Outlook | Price targets range from $80 to $102, averaging $91.25, reflecting mixed sentiment as DexCom balances market leadership against competitive threats from Abbott and potential regulatory hurdles. |
DexCom Inc Earnings Call Summary for Q3/2026
- Dexcom Q3 EPS of $0.73 beat estimates by 9%, revenue rose 11% YoY to $1.34B; gross margin improved 380bps to 65.1%, the highest since late 2022.
- Company raised FY 2026 revenue guidance to $5.20B-$5.25B (12-13% growth), operating margin to ~24%, and adjusted EBITDA margin to ~32%.
- U.S. revenue grew 14% to $970M driven by strong type 2 diabetes adoption; international sales up 5% to $375M, impacted by tough prior-year comparisons.
- G7 15 Day expected to reach 50% of U.S. customers by year-end; G8 launch targeted for late 2027/early 2028; Dexcom Direct service launching early 2027.
- Completed $1B share buyback program and authorized another $1B; generated $900M+ free cash flow through Q3 with $1.8B cash on hand.
Last Updated: 2026-10-29, 05:42 p/m
Read Full TranscriptEarnings
Latest Release
Oct 29, 2026
EPS / Forecast
0.73 / 0.67
Revenue / Forecast
1.34B / 1.33B
Compare DXCM to Peers and Sector
Metrics to compare | DXCM | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDXCMPeersSector | |
|---|---|---|---|---|
P/E Ratio | 30.0x | 24.8x | −0.2x | |
PEG Ratio | 0.71 | −0.91 | 0.00 | |
Price/Book | 11.7x | 2.8x | 2.6x | |
Price / LTM Sales | 5.8x | 3.2x | 2.8x | |
Upside (Analyst Target) | 22.7% | 4.8% | 62.1% | |
Fair Value Upside | Unlock | −5.1% | 9.5% | Unlock |
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the DexCom (DXCM) Stock Price Today?
The DexCom stock price today is 79.68 USD.
What Stock Exchange Does DexCom Trade On?
DexCom is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for DexCom?
The stock symbol for DexCom is "DXCM."
What Is the DexCom Market Cap?
As of today, DexCom market cap is 29.81B USD.
What Is DexCom's Earnings Per Share (TTM)?
The DexCom EPS (TTM) is 2.59.
When Is the Next DexCom Earnings Date?
DexCom will release its next earnings report on Feb 11, 2027.
From a Technical Analysis Perspective, Is DXCM a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has DexCom Stock Split?
DexCom has split 1 times.
How Many Employees Does DexCom Have?
DexCom has 11050 employees.
What is the current trading status of DexCom (DXCM)?
As of Nov 06, 2026, DexCom (DXCM) is trading at a price of 79.68 USD, with a previous close of 84.46 USD. The stock has fluctuated within a day range of 79.28 USD to 82.85 USD, while its 52-week range spans from 54.11 USD to 92.59 USD.
What Is DexCom (DXCM) Price Target According to Analysts?
The average 12-month price target for DexCom is 98.15 USD, with a high estimate of 120 USD and a low estimate of 79 USD. 26 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +23.19% Upside potential.
What Is the DXCM Premarket Price?
DXCM's last pre-market stock price is 83.45 USD. The pre-market share volume is 2,540.00, and the stock has decreased by -1.01, or -1.20%.
What Is the DXCM After Hours Price?
DXCM's last after hours stock price is 84.16 USD, the stock has decreased by -0.30, or -0.36%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.